Zobrazeno 1 - 10
of 21
pro vyhledávání: '"D E, Lehane"'
Publikováno v:
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 17(3)
Despite advances in neurosurgery, radiation oncology, and chemotherapy, the prognosis for glioblastoma multiforme remains poor, with a median survival time of 11-12 months. Cisplatin (cis-diamminedichlorideplatinum II) is one treatment for glioblasto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6e5afc0ced5c828a2985ce5917f0d458
https://pubmed.ncbi.nlm.nih.gov/9304534
https://pubmed.ncbi.nlm.nih.gov/9304534
Publikováno v:
Journal of Neuro-Ophthalmology. 17:195
Despite advances in neurosurgery, radiation oncology, and chemotherapy, the prognosis for glioblastoma multiforme remains poor, with a median survival time of 11-12 months. Cisplatin (cis-diamminedichlorideplatinum II) is one treatment for glioblasto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1758c45d7f85c58b1851100a084127b
https://doi.org/10.1097/00041327-199709000-00010
https://doi.org/10.1097/00041327-199709000-00010
Autor:
D. E. Lehane
Publikováno v:
JAMA: The Journal of the American Medical Association. 213:2236-2239
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a22bb302cabedb6b13dfd32d5df74af
https://doi.org/10.1001/jama.213.13.2236
https://doi.org/10.1001/jama.213.13.2236
Autor:
D. E. Lehane
Publikováno v:
Archives of Internal Medicine. 134:763-765
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::832ac1eabad090a32db23c8ccf12fc5a
https://doi.org/10.1001/archinte.134.4.763
https://doi.org/10.1001/archinte.134.4.763
Autor:
D E, Lehane
Publikováno v:
JAMA: The Journal of the American Medical Association. 212:2240-2242
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3669d39783a0d2ae631e63b034e0aab0
https://doi.org/10.1001/jama.212.13.2240
https://doi.org/10.1001/jama.212.13.2240
Publikováno v:
Cancer treatment reports. 69(6)
One hundred eligible patients with inoperable, locally advanced or metastatic squamous cell carcinoma of the head and neck region following prior therapy were randomized to receive im methotrexate (50 patients) or iv cisplatin (50 patients). Methotre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0312eaed848c7fb2b64c2a8d56703f71
https://pubmed.ncbi.nlm.nih.gov/4040421
https://pubmed.ncbi.nlm.nih.gov/4040421
Publikováno v:
Cancer chemotherapy reports. 59(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7c33cc13c228208ae2be8ea3d018f406
https://pubmed.ncbi.nlm.nih.gov/769959
https://pubmed.ncbi.nlm.nih.gov/769959
Publikováno v:
Cancer research. 37(7 Pt 1)
Sézary cells were studied in the peripheral blood and characteristic skin lesions of the Sézary syndrome and mycosis fungoides by transmission electron microscopy to obtain more information on their nuclear and nucleolar ultrastructure. Sézary cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::48854d597bb792564e5802c6f0b9a4ab
https://pubmed.ncbi.nlm.nih.gov/140762
https://pubmed.ncbi.nlm.nih.gov/140762
Publikováno v:
The American journal of medicine. 77(3)
In the first study of combined chemotherapy and radiation therapy for small cell lung cancer by the Southwest Oncology Group, 17 patients survived more than five years after treatment was initiated (4.6 percent). Late relapse, or a second primary mal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::91fa8621e5390dbea9a5ca482aaf9cb6
https://pubmed.ncbi.nlm.nih.gov/6089560
https://pubmed.ncbi.nlm.nih.gov/6089560
Autor:
L H, Baker, R W, Talley, R, Matter, D E, Lehane, B W, Ruffner, S E, Jones, F S, Morrison, R L, Stephens, E A, Gehan, V K, Vaitkevicius
Publikováno v:
Cancer. 38(1)
In a randomized and stratified study, 294 patients with advanced gastrointestinal cancer were treated either with 5-fluorouracil (5-FU) 400 mg/m2 weekly intravenously (i.v.) or 5-FU 400 mg/m2 i.v. weekly plus methyl-CCNU 175 mg/m2 orally (p.o.) every
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b332bfb7674905b1353709bb1944b91c
https://pubmed.ncbi.nlm.nih.gov/779949
https://pubmed.ncbi.nlm.nih.gov/779949